1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Drs. Hu and Wang contributed equally to this work.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Sjögren's Syndrome
You have full text access to this OnlineOpen article
Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome
Article first published online: 29 OCT 2007
DOI: 10.1002/art.22954
Copyright © 2007 by the American College of Rheumatology
Additional Information
How to Cite
Hu, S., Wang, J., Meijer, J., Ieong, S., Xie, Y., Yu, T., Zhou, H., Henry, S., Vissink, A., Pijpe, J., Kallenberg, C., Elashoff, D., Loo, J. A. and Wong, D. T. (2007), Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis & Rheumatism, 56: 3588–3600. doi: 10.1002/art.22954
- †
Drs. Hu and Wang contributed equally to this work.
- ‡
Dr. Kallenberg has received consulting fees, speaker's fees, or honoraria (less than $10,000 each) from Roche and La Jolla Pharmaceuticals.
Publication History
- Issue published online: 29 OCT 2007
- Article first published online: 29 OCT 2007
- Manuscript Accepted: 12 JUL 2007
- Manuscript Received: 14 JAN 2007
Funded by
- USPHS. Grant Numbers: R01-DE-17593, U01-DE-16275
- Abstract
- Article
- References
- Cited By
Abstract
Objective
To identify a panel of protein and messenger RNA (mRNA) biomarkers in human whole saliva (WS) that may be used in the detection of primary Sjögren's syndrome (SS).
Methods
Mass spectrometry and expression microarray profiling were used to identify candidate protein and mRNA biomarkers of primary SS in WS samples. Validation of the discovered mRNA and protein biomarkers was also demonstrated using real-time quantitative polymerase chain reaction and immunoblotting techniques.
Results
Sixteen WS proteins were found to be down-regulated and 25 WS proteins were found to be up-regulated in primary SS patients compared with matched healthy control subjects. These proteins reflected the damage of glandular cells and inflammation of the oral cavity system in patients with primary SS. In addition, 16 WS peptides (10 up-regulated and 6 down-regulated in primary SS) were found at significantly different levels (P < 0.05) in primary SS patients and controls. Using stringent criteria (3-fold change; P < 0.0005), 27 mRNA in saliva samples were found to be significantly up-regulated in the primary SS patients. Strikingly, 19 of 27 genes that were found to be overexpressed were interferon-inducible or were related to lymphocyte filtration and antigen presentation known to be involved in the pathogenesis of primary SS.
Conclusion
Our preliminary study has indicated that WS from patients with primary SS contains molecular signatures that reflect damaged glandular cells and an activated immune response in this autoimmune disease. These candidate proteomic and genomic biomarkers may improve the clinical detection of primary SS once they have been further validated. We also found that WS contains more informative proteins, peptides, and mRNA, as compared with gland-specific saliva, that can be used in generating candidate biomarkers for the detection of primary SS.